ArticleExperimental & molecular medicine2016
Generation and characterization of integration-free induced pluripotent stem cells from patients with autoimmune disease.
Article in Experimental & molecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Treatment of Sjögren's Syndrome with Mesenchymal Stem Cells: A Systematic Review.International journal of molecular sciences · 2021Pooled it
- Mesenchymal stromal cell therapy for systemic lupus erythematosus: mechanisms, clinical translation, and future directions.Stem cell research & therapy · 2026Review
- Application potential of induced pluripotent stem cells in the research and treatment of autoimmune diseases (Review).Molecular medicine reports · 2025Review
- Tracing genomic instability in induced mesenchymal stromal cell manufacture: an integration-free transfection approach.Experimental & molecular medicine · 2025Article
- Current cell therapies for systemic lupus erythematosus.Stem cells translational medicine · 2024Review
- Exploring gellan gum-based hydrogels for regenerating human embryonic stem cells in age-related macular degeneration therapy: A literature review.Regenerative therapy · 2024Review
- Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine.Current medicinal chemistry · 2024Review
- Investigation of immune-related diseases using patient-derived induced pluripotent stem cells.Inflammation and regeneration · 2023Review
- Lupus Heart Disease Modeling with Combination of Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Lupus Patient Serum.International journal of stem cells · 2022Article
- Gene delivery in adherent and suspension cells using the combined physical methods.Cytotechnology · 2022Article
- Article
- Induction of a local muscular dystrophy using electroporation in vivo: an easy tool for screening therapeutics.Scientific reports · 2020Article
- Stem cells: a potential treatment option for kidney diseases.Stem cell research & therapy · 2020Review
- Episomal Induced Pluripotent Stem Cells: Functional and Potential Therapeutic Applications.Cell transplantation · 2019Review
- The Post-GWAS Era: How to Validate the Contribution of Gene Variants in Lupus.Current rheumatology reports · 2019Review
- Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering.Experimental & molecular medicine · 2019Article
- Modelling cardiac fibrosis using three-dimensional cardiac microtissues derived from human embryonic stem cells.Journal of biological engineering · 2019Article
- Current Progress in Electrotransfection as a Nonviral Method for Gene Delivery.Molecular pharmaceutics · 2018Article
- Interleukin-2 induces the in vitro maturation of human pluripotent stem cell-derived intestinal organoids.Nature communications · 2018Article
- Comparative analysis of human embryonic stem cell‑derived neural stem cells as an in vitro human model.International journal of molecular medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune diseases (AIDs), a heterogeneous group of immune-mediated disorders, are a major and growing health problem. Although AIDs are currently treated primarily with anti-inflammatory and immunosuppressive drugs, the use of stem cell transplantation in patients with AIDs is becoming increasingly common. However, stem cell transplantation therapy has limitations, including a shortage of available stem cells and immune rejection of cells from nonautologous sources. Induced pluripotent stem cell (iPSC) technology, which allows the generation of patient-specific pluripotent stem cells, could offer an alternative source for clinical applications of stem cell therapies in AID patients. We used nonintegrating oriP/EBNA-1-based episomal vectors to reprogram dermal fibroblasts from patients with AIDs such as ankylosing spondylitis (AS), Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE). The pluripotency and multilineage differentiation capacity of each patient-specific iPSC line was validated. The safety of these iPSCs for use in stem cell transplantation is indicated by the fact that all AID-specific iPSCs are integrated transgene free. Finally, all AID-specific iPSCs derived in this study could be differentiated into cells of hematopoietic and mesenchymal lineages in vitro as shown by flow cytometric analysis and induction of terminal differentiation potential. Our results demonstrate the successful generation of integration-free iPSCs from patients with AS, SS and SLE. These findings support the possibility of using iPSC technology in autologous and allogeneic cell replacement therapy for various AIDs, including AS, SS and SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.